VSTA Financials 07/16/2014 00:32:39 VistaGen Ther

VSTA Financials 07/16/2014 00:32:39
VistaGen Therapeutics, Inc.
Period Ending Mar 31, 2014 Mar 31, 2013 Mar 31, 2012 Mar 31, 2011
Total Revenue - 200 1,342 2,071
Cost of Revenue - - - -
Gross Profit - 200 1,342 2,071
Operating Expenses
Research and Development 2,481 3,431 5,389 3,678
Sales, General and Admin. 2,548 3,563 4,997 4,958
Non-Recurring Items - - - -
Other - - - -
Operating Income (5,029) (6,793) (9,043) (6,565)
Income From Continuing Operations
Add'l Income/Expense Items 3,567 (5,169) (1,271) 204
Earnings Before Interest and Tax (1,462) (11,962) (10,315) (6,361)
Interest Expense 1,503 921 1,893 3,119
Earnings Before Tax (2,965) (12,883) (12,208) (9,481)
Income Tax 3 4 2 2
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,968) (16,455) (13,403) (9,482)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (2,968) (12,887) (12,210) (9,482)
Preferred Stock and Other Adjustments - (10,193) - -
Net Income Applicable to Common Shareholders (2,968) (23,080) (12,210) (9,482)